FDA Rejects Aldeyra's Dry Eye Disease Drug Reproxalap for Third Time, Citing Insufficient Efficacy
Key Insights
The FDA declined to approve Aldeyra Therapeutics' reproxalap for dry eye disease, marking the company's third consecutive regulatory setback since 2023.
The complete response letter cited insufficient efficacy data while raising no safety or manufacturing concerns for the drug.
Aldeyra shares plunged over 70% in premarket trading following the announcement, with the company planning to request a Type A meeting with the FDA.
The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' reproxalap for the treatment of dry eye disease, delivering a significant blow to the company and sending its shares plummeting over 70% in premarket trading on Tuesday.
The regulatory rejection, communicated through a complete response letter, specifically cited the drug's failure to demonstrate sufficient efficacy for approval. However, the FDA raised no concerns regarding safety or manufacturing aspects of reproxalap, according to Aldeyra's announcement.
Third Consecutive Regulatory Setback
This latest decision represents the third consecutive setback for Aldeyra, which has encountered repeated regulatory challenges since 2023 related to reproxalap. The pattern of rejections highlights the ongoing difficulties the company faces in meeting FDA efficacy standards for this indication.
Reproxalap is designed to treat dry eye disease (DED), a condition characterized by insufficient or poor-quality tear production that leads to discomfort and potential vision problems. The condition affects nearly 16.4 million Americans, with higher prevalence observed in women and increasing frequency with age, according to the National Institutes of Health.
Company Response and Next Steps
Following the FDA's decision, Aldeyra announced it does not currently plan to conduct additional clinical trials. Instead, the company will request a Type A meeting with the FDA to discuss the specific requirements needed to secure approval.
The FDA has advised Aldeyra to investigate what factors contributed to the trial failures and to identify specific patient groups or conditions where reproxalap may demonstrate effectiveness. Notably, the agency did not request new trials or additional confirmatory evidence as part of its guidance.
Financial Position
As of December 31, Aldeyra reported having $70 million in cash, cash equivalents, and marketable securities, which the company expects will fund operations into 2028. This financial runway provides some stability as the company navigates its regulatory challenges and determines its path forward with reproxalap development.